Navigation Links
Why tumors become resistant to chemotherapy?
Date:12/2/2013

A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance", but today the group Manel Esteller, Director of Epigenetics and Cancer Biology at the Bellvitge Biomedical Research Institute (IDIBELL) , ICREA researcher and Professor of Genetics at the University of Barcelona, describes in the official Journal of the National Cancer Research Center in the United States , The Journal of The National Cancer Institute, the existence of epigenetic differences that explain the lack of response of the tumor recurs.

"We studied colon cancer cells that were initially sensitive to oxaliplatin drug and then became insensitive to this drug and we found that resistant tumors had inactivated a gene (SRBC) in their DNA" says Manel Esteller "the loss of activity supposedly happens in a gene involved in DNA repair. Thus these tumor cells, when receiving the drug, quickly repair the effect thereof and do not die. Studying nearly two hundred patients with colon cancer also found that inactivation of the gene is associated with poorer survival of these people despite treatment. Interestingly the loss of function of this gene could also explain why some colon tumors are resistant from the outset, what is known as "primary resistance " concludes Esteller.

The discovery could have important implications for personalized treatment of colon cancer. If these findings extend to other clinical trials, determining the activation state of the SRBC gene could be useful in deciding whether a patient should receive a type of drug or another. Likewise the use of another class of drugs that return gen activity (epigenetic drugs) could restore the sensitivity to the original drug , oxaliplatin .

Finally, a very promising door is opened to examine whether similar mechanisms are happening in other human tumors beyond colon cancer.


'/>"/>

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert  

Related medicine news :

1. New immunotherapy for malignant brain tumors
2. Biomaterial-delivered chemotherapy could provide final blow to brain tumors
3. Oxygen levels in tumors affect response to treatment
4. Special camera detects tumors
5. Cell Phone Radiation Lawsuit Update: Bernstein Liebhard LLP Comments on Latest Research into Cell Phone Use and Brain Tumors
6. APAC Solid Tumors Market to Grow at a CAGR of 12.3% to 2019 in New Research Report at RnRMarketResearch.com
7. Join the Fight Against Brain Tumors & Get Healthy at the Brain Tumor Run for Research 5k on October 19th
8. New system uses nanodiamonds to deliver chemotherapy drugs directly to brain tumors
9. Bone growth factor may increase benign tumors but not malignant cancer
10. New Way to Track Stem Cell Migration Could Advance Treatments for Brain Tumors and More
11. Voices Against Brain Cancer Comments on New Technique Being Used by Surgeons that Lights Up Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Why tumors become resistant to chemotherapy?
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
Breaking Medicine Technology: